{"pii": "S1059131122002151", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "abstract", "$": {"id": "abs0001", "class": "author-highlights", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0001"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abss0001", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "spara009", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "celist0001"}, "$$": [{"#name": "list-item", "$": {"id": "celistitem0001"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "para0001", "view": "all"}, "_": "Phenobarbital and high-dose levetiracetam are more effective for treatment of benzodiazepine-resistant status epilepticus."}]}, {"#name": "list-item", "$": {"id": "celistitem0002"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "para0002", "view": "all"}, "_": "Phenobarbital was associated with a higher risk of intubation and cardiovascular instability."}]}, {"#name": "list-item", "$": {"id": "celistitem0003"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "para0003", "view": "all"}, "_": "Choice of medication may be guided by effectiveness, safety concerns, availability and cost."}]}]}]}]}]}, {"#name": "abstract", "$": {"id": "abs0002", "view": "all", "class": "author"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0002"}, "_": "Abstract"}, {"#name": "abstract-sec", "$": {"id": "abss0003", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0003"}, "_": "Purpose"}, {"#name": "simple-para", "$": {"id": "spara010", "view": "all"}, "_": "Multiple interventions have been studied for benzodiazepine-resistant status epilepticus (SE) in children and adults. This review aimed to summarize the available evidence and provide estimates of comparative effectiveness and ranking of treatment effects."}]}, {"#name": "abstract-sec", "$": {"id": "abss0004", "role": "materials-methods", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0004"}, "_": "Methods"}, {"#name": "simple-para", "$": {"id": "spara011", "view": "all"}, "_": "All randomized controlled trials studying patients (>1 month of age) with benzodiazepine-resistant SE were included. Outcomes including seizure cessation within 60\u00a0min, seizure freedom for 24\u00a0h, death, respiratory depression warranting intubation and cardiovascular instability were studied. Conventional and network meta-analyses (NMA) were done."}]}, {"#name": "abstract-sec", "$": {"id": "abss0005", "role": "results", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0005"}, "_": "Results"}, {"#name": "simple-para", "$": {"id": "spara012", "view": "all"}, "_": "Seventeen studies were included (16 in NMA). Phenobarbital and high-dose levetiracetam were significantly superior to phenytoin with respect to seizure cessation within 60\u00a0min. Network ranking demonstrated that phenobarbital had the highest probability of being the best among the studied interventions followed by high-dose levetiracetam and high-dose valproate. Network meta-analysis was limited by predominant indirect evidence and high heterogeneity.On pairwise comparisons, phenobarbital was found to be associated with a higher risk of need for intubation and cardiovascular instability. Levetiracetam had a better safety profile than fosphenytoin."}]}, {"#name": "abstract-sec", "$": {"id": "abss0006", "role": "conclusion", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "cesectitle0006"}, "_": "Conclusions"}, {"#name": "simple-para", "$": {"id": "spara013", "view": "all"}, "_": "Based on low quality evidence, phenobarbital appears to be the most effective agent for seizure cessation within 60\u00a0min of administration in patients with benzodiazepine resistant status epilepticus. High-dose levetiracetam, high-dose valproate and fosphenytoin are probably equally effective. Choice of medication may be guided by effectiveness, safety concerns, availability, cost and systemic co-morbidities."}]}]}]}}